Literature DB >> 21585224

The new EU legislation on pharmacovigilance and changing models for drug development.

Torbjörn Callréus.   

Abstract

Mesh:

Year:  2011        PMID: 21585224     DOI: 10.2165/11592380-000000000-00000

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


× No keyword cloud information.
  5 in total

1.  Where will new drugs come from?

Authors: 
Journal:  Lancet       Date:  2011-01-08       Impact factor: 79.321

Review 2.  Beyond debacle and debate: developing solutions in drug safety.

Authors:  Amrit Ray
Journal:  Nat Rev Drug Discov       Date:  2009-09-18       Impact factor: 84.694

Review 3.  The future of drug development: advancing clinical trial design.

Authors:  John Orloff; Frank Douglas; Jose Pinheiro; Susan Levinson; Michael Branson; Pravin Chaturvedi; Ene Ette; Paul Gallo; Gigi Hirsch; Cyrus Mehta; Nitin Patel; Sameer Sabir; Stacy Springs; Donald Stanski; Matthias R Evers; Edd Fleming; Navjot Singh; Tony Tramontin; Howard Golub
Journal:  Nat Rev Drug Discov       Date:  2009-10-09       Impact factor: 84.694

4.  A basic study design for expedited safety signal evaluation based on electronic healthcare data.

Authors:  Sebastian Schneeweiss
Journal:  Pharmacoepidemiol Drug Saf       Date:  2010-08       Impact factor: 2.890

Review 5.  Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.

Authors:  John-Joseph Borg; George Aislaitner; Michal Pirozynski; Stephen Mifsud
Journal:  Drug Saf       Date:  2011-03-01       Impact factor: 5.606

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.